Currently Viewing:
Currently Reading
Bone Marrow Environment in Patients With RA May Promote Inflammation
December 12, 2017 – Kelly Davio
Researchers Say Medicare Advantage Plans Need Better Incentives to Meet Future Demand
December 12, 2017 – Allison Inserro
University, Genetics Firm Find Link Between ADHD, Delay Discounting
December 12, 2017 – Allison Inserro
Welltok Identifies Who's at Risk for Getting and Spreading the Flu
December 12, 2017 – Jaime Rosenberg
What We're Reading: Medical Device Approval; Medical Laboratories Sue Government; ACA Sign-Up Deadline
December 12, 2017 – AJMC Staff
What's the Magic Payment Mix for Medicare Primary Care Providers?
December 11, 2017 – Allison Inserro
Racial Disparities Prevalent in Survival of Patients With Ovarian, Colon, and Breast Cancer
December 11, 2017 – Jaime Rosenberg
Sanofi's Insulin Lispro Follow-On, Admelog, Wins FDA Approval
December 11, 2017 – Mary Caffrey
The Past, Present, and Future of HIV Funding
December 11, 2017 – Jaime Rosenberg

Positive Results From Phase 3 Study of Intuniv in Adults With ADHD

AJMC Staff
Intuniv, a once-daily non-stimulant from Shire and Shionogi for adults with attention-deficit/hyperactivity disorder, met its primary endpoint and showed a superior change from baseline compared with placebo in a phase 3 study.
Shire and Shionogi’s Intuniv, a once-daily non-stimulant for adults with attention-deficit/hyperactivity disorder (ADHD), met its primary endpoint and showed a superior change from baseline compared with placebo in a phase 3 study.

The study included adults in Japan age 18 years and older who had ADHD. The drug is already approved as a treatment for patients between the ages of 6 and 17 years in Japan, the United States, and other countries, and is now being evaluated in Japan to treat ADHD in adults. Japan is the third-largest market for ADHD.

This 12-week, randomized, double-blind, multi-center, placebo-controlled study was the first clinical trial evaluating Intuniv in adults. A total of 201 adult patients with ADHD participated in the study. The study showed that Intuniv was superior to placebo based on a clinically administered ADHD rating scale total score. The treatment was also superior to placebo in improving patients’ global functioning.

“The positive topline results of this phase 3 study provide us with important data and insights regarding the clinical profile of Intuniv in adult patients with ADHD,” Brigitte Robertson, MD, vice president and head of Global Clinical Development, Neuropsychiatry, Shire, said in a statement. “We are evaluating the full data set, and excited to advance the development of INTUNIV as a non-stimulant treatment option for adults with ADHD in Japan, building on the established efficacy and safety data for ADHD in child and adolescent patients.”

Adverse events in the study were mild to moderate, and the researchers reported no new or unexpected safety findings compared with previous Intuniv studies. The most common adverse events were somnolence, dry mouth, blood pressure decrease, nospharyngitis, dizziness postural, and constipation.

Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up

Sign In

Not a member? Sign up now!